Xiamen Innovax Biotech
CompanyChina
Xiamen Innovax Biotech develops 3 assets, the furthest in phase 3 (Cervarix in cervical intraepithelial neoplasia). Mostly vaccine; based in China.
- 3
- Assets
- Furthest
- Phase 3
- 7
- Trials
- 0
- Signals
Pipeline
3Recombinant vaccine preventing infection by oncogenic human papillomaviruses
Phase 3, Vaccine, cervical intraepithelial neoplasia, human papillomavirus vaccine
Recombinant Hepatitis E Vaccine (Escherichia Coli)
Induces protective immunity against hepatitis E virus using recombinant viral antigen.
Phase 3, Vaccine, cervical cancer, cervical intraepithelial neoplasia
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Induces neutralizing antibodies against human papillomavirus types 16 and 18 to prevent infection and associated lesions.
Phase 3, Vaccine, cervical cancer, cervical intraepithelial neoplasia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials10
- Similar companies3
Updated 12 Oct 2026 · 24 sources